Endogenous retrovirus activation: potential for immunology and clinical applications

Endogenous retroviruses (ERVs), the remnants of ancient retrovirus infections, constitute approximately 8% of the human genome and play important roles in human evolution, development, and diseases.Multiple drugs, such as DNA methyltransferase inhibitors and lysine-specific histone demethylase 1 inhibitors, reactivate ERVs,